8 results about "Infarct volume" patented technology

This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.

The invention belongs to the technical field of medicines, and discloses application of a magnolol nitrone derivative HL-3 in preparation of medicines for preventing or treating cerebral infarction. The HL-3 shows a remarkable treatment effect in both in-vitro and in-vivo experiments. In an in-vitro experiment, the HL-3 can effectively relieve damage caused by oxygen glucose deprivation / reoxygenation (OGDR) of SK-N-SH cells under the concentration of 10 micromoles (mu M), the cell survival rate is remarkably increased, and it is indicated that the HL-3 has a high neuroprotective effect. In an integral animal experiment, the HL-3 shows an obvious treatment effect on transient middle cerebral artery occlusion (tMCAO) and permanent middle cerebral artery occlusion (pMCAO) models of SD (Sprague Dawley) rats under the dosage of 1mg / kg and 10mg / kg. Specifically, the cerebral infarction volume is reduced, and the neurological function score is improved. The results show that the HL-3 is effective in various models, has wide applicability and remarkable treatment potential, and provides a new and effective drug choice for cerebral infarction treatment.

The invention relates to the technical field of stem cells, and provides application of a mesenchymal stem cell exosome subdivision subgroup in cerebral apoplexy treatment. Compared with undivided subgroups and positive drugs, the exosome subgroups S1 and S2 have the advantages that the effects of improving post-stroke neurological functions and reducing infarct volumes are more remarkable, the purity is high, large-scale preparation can be realized, and good preparations or drug products can be formed. The invention provides a new treatment scheme for cerebral apoplexy treatment, and has a good application prospect.

The invention belongs to the technical field of ischemic stroke treatment, and discloses application of ULK1 possibly serving as a target spot for treating ischemic stroke. According to the invention, a photothrombotic stroke model is established, a ULK1 inhibitor SBI-0206965 (SBI), LYN1604 hydrochloride (LYN) and a ULK1 agonist are administered, and the ULK1 agonist is used for regulating the activity of ULK1 in vivo. Examples assess the outcome of sensory motor deficits, neuronal apoptosis, and microglia / macrophage activated neurological function. Immunofluorescence detection results show that ULK1 is mainly located in microglial cells in a post-ischemic infarction area of China. Upregulated ULK1 is treated by LYN, so that the infarct volume is remarkably reduced, the motor function is improved, and the increase of inflammatory microglial cells is promoted. In conclusion, the ULK1 promotes the repair of neurons and promotes the formation of 13 paths of anti-inflammatory microglial cell paths after ischemic injury.

The invention discloses an application of a bruscin compound in preparation of a medicine for treating acute cerebral ischemic stroke. The invention provides an application of a brusicin compound containing a quassin diterpene mother nucleus in preparation of a medicine for inhibiting PARthanatos, and further provides an application of brucein E in preparation of a medicine for treating cerebral apoplexy, a medicine for treating cerebral ischemia-reperfusion injury and a PARP-1 inhibitor. According to the application disclosed by the invention, the brucein E is screened and identified to become a potent inhibitor of PARthanaos due to inhibition of excessive activation of PARP-1 at a nanomolar concentration. The brucein E effectively prevents accumulation of PAR modified protein, reduces mitochondrial membrane potential collapse and inhibits AIF nuclear translocation. The brucein E can greatly reduce the infarct volume and denatured neurons, increases the microvascular density, has no adverse effect on cerebral blood flow, and shows the potential of single-time, delayed and low-dose central protection.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for preventing and treating acute ischemic stroke and a preparation method thereof. Aiming at the acute pathogenesis of qi and blood disorder, phlegm and blood stasis and wind-fire internal movement, the system compatibility of monarch, minister, assistant and guide is followed; prepared leech and salvia miltiorrhiza are used as monarch drugs; earthworm and radix curcumae are used as ministerial drugs; gastrodia elata, rhizoma acori graminei, radix scrophulariae and dendrobe are And radix cyathulae and liquorice are used as conductant drugs. In a mouse middle cerebral artery embolism model, the medicine is continuously administered for 7 days according to a preset dosage, the cerebral infarction volume is obviously reduced, and the neurological function score is obviously improved; and the levels of MMP-9 and TNF-alpha in serum are both reduced. The toxicity of animal weight, liver and kidney functions and blood routine indexes is not obviously changed, and the safety is good. According to the invention, a stable preparation process of first decoction of leeches, double decoction, alcohol precipitation and low-temperature drying is established, so that key components are kept in a stable release state in the extraction and concentration process, and the consistency and controllability of the quality of the preparation are realized.

The presently-disclosed subject matter generally to methods for identifying and analyzing biomarkers to determine group effects. The presently-disclosed subject matter also relates to methods for identifying genes and proteins that increase or decrease in response to ischemic stroke damage. The disclosed subject matter further describes methods of predicting edema and infarct volume in a patient. Also described herein are methods of determining the necessity of intervention for smokers. Further disclosed herein, are methods for testing therapies for ischemic stroke.

The invention relates to the technical field of intelligent medical assistance, in particular to a method, device and equipment for assisting stroke assessment and a medium, and the method comprises the steps: receiving a brain image, clinical vital sign data, pre-hospital first-aid records and historical health data; the method comprises the following steps of: extracting deep semantic features of a brain image by adopting a convolutional neural network and a Swinin-Transform hybrid encoder; a gradient boosting tree feature encoder is adopted to extract nonlinear correlation features among the clinical vital sign data, the pre-hospital emergency records and the historical health data; based on the deep semantic features and the nonlinear correlation features, adopting residual connection and a multi-head attention mechanism to obtain complementary fusion features; determining the stroke type based on the fusion features; and when ischemic stroke is determined, the volume of a core infarction region is measured and calculated, so that the assessment time of the emergency stroke is shortened.